How to Ensure Access Doesn’t Get in the Way of Good Science

2:00 PM - 3:00 PM, Tuesday, June 4,2019 ・ 111AB, Level 100
Overcoming obstacles that hinder integration of real world data into current clinical development is becoming more critical. Yet organizations are limited by practical constraints (divergent business objectives and poor interface among stakeholders) and scientific boundaries (myopic focus on primary endpoints and early pipeline risk of candidate attrition). While there has been some investment into novel initiatives to further inform development, general application is a challenge. This session takes a unique perspective, through the lens of a clinical program team, to demonstrate how pharma can improve hit rate and profitability, drive efficiencies in development, establsh optimal pricing for the market and increase commercial value.
Speakers
photo
Chief Business Officer
Eiger BioPharmaceuticals
photo
Chief Strategy & Development Officer
Aquestive Therapeutics
photo
Vice President, Global Healthcare Innovation Lead
Pfizer Inc.
photo
Vice President, U.S. Medical Affairs, Customer Engagement, Value, Evidence & Outcomes
GlaxoSmithKline